Rachel E. Caves
University of Leicester
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Rachel E. Caves.
Cell Death & Differentiation | 2012
Shankar Varadarajan; Edward T. W. Bampton; Joshua L. Smalley; Kayoko Tanaka; Rachel E. Caves; Michael Butterworth; Jun Wei; Maurizio Pellecchia; John S. Mitcheson; Timothy W. Gant; David Dinsdale; Gerald M. Cohen
Canonical endoplasmic reticulum (ER) stress, which occurs in many physiological and disease processes, results in activation of the unfolded protein response (UPR). We now describe a new, evolutionarily conserved cellular stress response characterised by a striking, but reversible, reorganisation of ER membranes that occurs independently of the UPR, resulting in impaired ER transport and function. This reorganisation is characterised by a dramatic redistribution and clustering of ER membrane proteins. ER membrane aggregation is regulated, in part, by anti-apoptotic BCL-2 family members, particularly MCL-1. Using connectivity mapping, we report the widespread occurrence of this stress response by identifying several structurally diverse chemicals from different pharmacological classes, including antihistamines, antimalarials and antipsychotics, which induce ER membrane reorganisation. Furthermore, we demonstrate the potential of ER membrane aggregation to result in pathological consequences, such as the long-QT syndrome, a cardiac arrhythmic abnormality, arising because of a novel trafficking defect of the human ether-a-go-go-related channel protein from the ER to the plasma membrane. Thus, ER membrane reorganisation is a feature of a new cellular stress pathway, clearly distinct from the UPR, with important consequences affecting the normal functioning of the ER.
Heart Rhythm | 2017
Rachel E. Caves; Hongwei Cheng; Stéphanie C.M. Choisy; Hanne C. Gadeberg; Simon M. Bryant; Jules C. Hancox; Andrew F. James
Background Class 1 antiarrhythmic drugs are highly effective in restoring and maintaining sinus rhythm in atrial fibrillation patients but carry a risk of ventricular tachyarrhythmia. The antianginal agent ranolazine is a prototypic atrial-selective voltage-gated Na+ channel blocker but the mechanisms underlying its atrial-selective action remain unclear. Objective The present study examined the mechanisms underlying the atrial-selective action of ranolazine. Methods Whole-cell voltage-gated Na+ currents (INa) were recorded at room temperature (∼22°C) from rabbit isolated left atrial and right ventricular myocytes. Results INa conductance density was ∼1.8-fold greater in atrial than in ventricular cells. Atrial INa was activated at command potentials ∼7 mV more negative and inactivated at conditioning potentials ∼11 mV more negative than ventricular INa. The onset of inactivation of INa was faster in atrial cells than in ventricular myocytes. Ranolazine (30 μM) inhibited INa in atrial and ventricular myocytes in a use-dependent manner consistent with preferential activated/inactivated state block. Ranolazine caused a significantly greater negative shift in voltage of half-maximal inactivation in atrial cells than in ventricular cells, the recovery from inactivation of INa was slowed by ranolazine to a greater extent in atrial myocytes than in ventricular cells, and ranolazine produced an instantaneous block that showed marked voltage dependence in atrial cells. Conclusion Differences exist between rabbit atrial and ventricular myocytes in the biophysical properties of INa. The more negative voltage dependence of INa activation and inactivation, together with trapping of the drug in the inactivated channel, underlies an atrial-selective action of ranolazine.
Journal of Medicinal Chemistry | 2012
Andrea Cavalli; Rosa Buonfiglio; Cristina Ianni; Matteo Masetti; Luisa Ceccarini; Rachel E. Caves; Michael W. Y. Chang; John S. Mitcheson; Marinella Roberti; Maurizio Recanatini
Biochemistry | 2018
Neil Bate; Rachel E. Caves; Simon P. Skinner; Benjamin T. Goult; Jaswir Basran; John S. Mitcheson; Geerten W. Vuister
Biophysical Journal | 2018
Rachel E. Caves; Stéphanie C.M. Choisy; Simon M. Bryant; Jules C. Hancox; Andrew F. James
Heart Rhythm | 2017
Rachel E. Caves; Hongwei Cheng; Stéphanie C.M. Choisy; Hanne C. Gadeberg; Simon M. Bryant; Jules C. Hancox; Andrew F. James
Biophysical Journal | 2017
Rachel E. Caves; Hongwei Cheng; Stéphanie C.M. Choisy; Hanne C. Gadeberg; Simon M. Bryant; Jules C. Hancox; Andrew F. James
Biophysical Journal | 2014
Rachel E. Caves; Kieran E. Brack; Andre Ng; John S. Mitcheson
The FASEB Journal | 2013
Kieran E. Brack; Rachel E. Caves; G. André Ng; John S. Mitcheson
Biophysical Journal | 2013
Rachel E. Caves; Kieran E. Brack; Andre Ng; John S. Mitcheson